Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Apr 29

PMID 32340119

Citations 6

Authors

Marti Farrera-Sal

Cristina Fillat

Ramon Alemany

Affiliations

Soon will be listed here.

Abstract

Clinical results with oncolytic adenoviruses (OAds) used as antitumor monotherapies show limited efficacy. To increase OAd potency, transgenes have been inserted into their genome, a strategy known as "arming OAds". Here, we review different parameters that affect the outcome of armed OAds. Recombinant adenovirus used in gene therapy and vaccination have been the basis for the design of armed OAds. Hence, early region 1 (E1) and early region 3 (E3) have been the most commonly used transgene insertion sites, along with partially or complete E3 deletions. Besides transgene location and orientation, transcriptional control elements, transgene function, either virocentric or immunocentric, and even the codons encoding it, greatly impact on transgene levels and virus fitness.

Citing Articles

Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.

Robert S, Roman Ortiz N, LaRocca C, Ostrander J, Davydova J Viruses. 2024; 16(4).

PMID: 38675909 PMC: 11054319. DOI: 10.3390/v16040567.

The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment .

Higgins T, Patton D, Shimko-Lofano I, Eller T, Molinari R, Sandey M Cells. 2024; 13(4.

PMID: 38391964 PMC: 10886739. DOI: 10.3390/cells13040351.

The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus.

Pathak U, Pal R, Malik N Life (Basel). 2023; 13(8).

PMID: 37629483 PMC: 10455894. DOI: 10.3390/life13081626.

Evaluation of a Novel Oncolytic Adenovirus Silencing .

Vermeulen C, Brachtlova T, Tol N, van der Meulen-Muileman I, Hodzic J, van de Vrugt H Int J Mol Sci. 2022; 23(23).

PMID: 36499754 PMC: 9737683. DOI: 10.3390/ijms232315430.

Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.

Wang Q, Ma X, Wu H, Zhao C, Chen J, Li R Oncoimmunology. 2022; 11(1):2096362.

PMID: 35800156 PMC: 9255048. DOI: 10.1080/2162402X.2022.2096362.

References

Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L . Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther. 2005; 16(7):845-58. DOI: 10.1089/hum.2005.16.845. View

Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z . Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells. Biochem Biophys Res Commun. 2017; 491(1):134-139. DOI: 10.1016/j.bbrc.2017.07.062. View

Sauthoff H, Pipiya T, Heitner S, Chen S, Norman R, Rom W . Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther. 2002; 13(15):1859-71. DOI: 10.1089/104303402760372954. View

Oh E, Choi I, Hong J, Yun C . Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model. Oncotarget. 2016; 8(3):4730-4746. PMC: 5354867. DOI: 10.18632/oncotarget.13972. View

Szymczak A, Workman C, Wang Y, Vignali K, Dilioglou S, Vanin E . Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol. 2004; 22(5):589-94. DOI: 10.1038/nbt957. View

Xie W, Hao J, Zhang K, Fang X, Liu X . Adenovirus armed with VGLL4 selectively kills hepatocellular carcinoma with G2/M phase arrest and apoptosis promotion. Biochem Biophys Res Commun. 2018; 503(4):2758-2763. DOI: 10.1016/j.bbrc.2018.08.036. View

Ashshi A, El-Shemi A, Dmitriev I, Kashentseva E, Curiel D . Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer. J Ovarian Res. 2016; 9(1):38. PMC: 4924320. DOI: 10.1186/s13048-016-0248-5. View

Zhang Y, Nemunaitis J, Samuel S, Chen P, Shen Y, Tong A . Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006; 66(19):9736-43. DOI: 10.1158/0008-5472.CAN-06-1617. View

Bauzon M, Castro D, Karr M, Hawkins L, Hermiston T . Multigene expression from a replicating adenovirus using native viral promoters. Mol Ther. 2003; 7(4):526-34. DOI: 10.1016/s1525-0016(03)00023-6. View

10.

Guedan S, Rojas J, Gros A, Mercade E, Cascallo M, Alemany R . Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther. 2010; 18(7):1275-83. PMC: 2911260. DOI: 10.1038/mt.2010.79. View

11.

Sarkar D, Lebedeva I, Su Z, Park E, Chatman L, Vozhilla N . Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 2007; 67(11):5434-42. DOI: 10.1158/0008-5472.CAN-07-0195. View

12.

Ganesh S, Edick M, Idamakanti N, Abramova M, VanRoey M, Robinson M . Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007; 67(9):4399-407. DOI: 10.1158/0008-5472.CAN-06-4260. View

13.

Fang L, Cheng Q, Liu W, Zhang J, Ge Y, Zhang Q . Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. Cancer Biol Ther. 2016; 17(6):664-73. PMC: 4990404. DOI: 10.1080/15384047.2016.1190485. View

14.

Vassilev L, Ranki T, Joensuu T, Jager E, Karbach J, Wahle C . Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8 T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology. 2015; 4(7):e1017702. PMC: 4485730. DOI: 10.1080/2162402X.2015.1017702. View

15.

Rivera-Molina Y, Jiang H, Fueyo J, Nguyen T, Shin D, Youssef G . GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv. 2019; 1(1):vdz009. PMC: 6777503. DOI: 10.1093/noajnl/vdz009. View

16.

Fajardo C, Guedan S, Rojas L, Moreno R, Arias-Badia M, Sostoa J . Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. Cancer Res. 2017; 77(8):2052-2063. DOI: 10.1158/0008-5472.CAN-16-1708. View

17.

Suzuki K, Alemany R, Yamamoto M, Curiel D . The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res. 2002; 8(11):3348-59. View

18.

Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, Watanabe J . Developing novel oncolytic adenoviruses through bioselection. J Virol. 2003; 77(4):2640-50. PMC: 141112. DOI: 10.1128/jvi.77.4.2640-2650.2003. View

19.

Singleton D, Li D, Bai S, Syddall S, Smaill J, Shen Y . The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Ther. 2007; 14(12):953-67. DOI: 10.1038/sj.cgt.7701088. View

20.

Hermening S, Kugler S, Bahr M, Isenmann S . Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron sequence. J Virol Methods. 2004; 122(1):73-7. DOI: 10.1016/j.jviromet.2004.08.005. View